Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of cediranib maleate when given
together with cilengitide in treating patients with progressive or recurrent glioblastoma.
Cediranib maleate and cilengitide may stop the growth of tumor cells by blocking blood flow
to the tumor. Giving cediranib maleate together with cilengitide may kill more tumor cells.